References
- Moore RA. The hidden costs of arthritis treatment and the cost of new therapy: the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology 2002; 41 Suppl 1: 7–15
- Wolfe MM, Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99
- Haslock I. Clinical economics review: gastrointestinal complications of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1998; 12: 127–33
- Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 Suppl 1B: 31S–8S
- Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16
- Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727–34
- Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strategies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med 1992; 152: 1145–55
- Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135–40
- Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8
- Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. J Am Med Assoc 1999; 282: 1921–8
- Lanas A. Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology 2002; 41 Suppl 1: 16–22
- Meagher EA. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors. Clinical implications. Drug Safety 2003; 26: 913–24
- Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001; 286: 954–9
- Wallace JL. Mechanisms of protection and healing: current knowledge and future research. Am J Med 2001; 110 Suppl 1A: 19S–23S
- Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 173–9
- Sharma RK, Raud J, Hoogstraate J, Berge O, AstraZeneca LP, Wilmington DE. AZD3582, a COX-inhibiting nitric oxide donator (CINOD), reduces pain, inflammation and fever in rats. Clin Pharmacol Ther 2003; 73: P54
- Hoogstraate J, Berge O, Ojteg G, Andersson LI. COX-inhibiting nitric oxide donator (CINOD): a new concept in the treatment of pain and inflammation. Ann Rheum Dis 2003; 62 Suppl 1: THU0084
- Sharma RK, Ojteg G, Mannine A, Hallgren A, Hoogstraate J, AstraZeneca LP, Wilmington DE. AZD3582, a COX-inhibiting nitric oxide donator (CINOD): gastric tolerability profile in the rat. Clin Pharmacol Ther 2003; 73: P53
- Wallace JL, Ojteg G, Andersson LI, Hoogstraate J. AZD3582 produces fewer and smaller gastric ulcers than naproxen in the rat refeeding model. Ann Rheum Dis 2003; 62 Suppl 1: AB0055
- Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003; 52: 1537–42
- Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–9
- Hawkey C, O'Morain C, Murray F, McCarthy C, Tierney D, Devane J. Two comparative endoscopic evaluations of Naprelan. Am J Orthop 1996; 25 Suppl 9: 30–6
- Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. Clin Pharmacol 2000; 40: 1109–20
- James MW, Hawkey CJ. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 2003; 56: 146–55
- Lohmander, S, McKeith, D, Svensson, O, Malmenäs, M, Bolin, L, Kalla, A, et al., A randomised, placebo-controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005;64:449–56.